Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.

Streckmann F, Hess V, Bloch W, Décard BF, Ritzmann R, Lehmann HC, Balke M, Koliamitra C, Oschwald V, Elter T, Zahner L, Donath L, Roth R, Faude O.

BMJ Open. 2019 Apr 24;9(4):e024467. doi: 10.1136/bmjopen-2018-024467.

2.

Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.

Bühl L, Abel T, Wolf F, Oberste M, Bloch W, Hallek M, Elter T, Zimmer P.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419832358. doi: 10.1177/1534735419832358.

3.

Aerobic physical exercise for adult patients with haematological malignancies.

Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N.

Cochrane Database Syst Rev. 2019 Jan 31;1:CD009075. doi: 10.1002/14651858.CD009075.pub3.

4.

Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial.

Streckmann F, Lehmann HC, Balke M, Schenk A, Oberste M, Heller A, Schürhörster A, Elter T, Bloch W, Baumann FT.

Support Care Cancer. 2019 Jul;27(7):2471-2478. doi: 10.1007/s00520-018-4531-4. Epub 2018 Oct 31.

PMID:
30382392
5.

The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP.

Streckmann F, Balke M, Lehmann HC, Rustler V, Koliamitra C, Elter T, Hallek M, Leitzmann M, Steinmetz T, Heinen P, Baumann FT, Bloch W.

BMC Cancer. 2018 Jan 10;18(1):62. doi: 10.1186/s12885-017-3866-4.

6.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.

Eur J Haematol. 2017 Mar;98(3):254-262. doi: 10.1111/ejh.12825. Epub 2016 Dec 1.

PMID:
27862308
7.

Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial.

Zimmer P, Oberste M, Bloch W, Schenk A, Joisten N, Hartig P, Wolf F, Baumann FT, Garthe A, Hallek M, Elter T.

Contemp Clin Trials. 2016 Jul;49:1-5. doi: 10.1016/j.cct.2016.05.007. Epub 2016 May 31.

PMID:
27261170
8.

Effects of Exercise Interventions and Physical Activity Behavior on Cancer Related Cognitive Impairments: A Systematic Review.

Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, Elter T, Galvao DA, Bloch W, Hübner ST, Wolf F.

Biomed Res Int. 2016;2016:1820954. doi: 10.1155/2016/1820954. Epub 2016 Apr 10. Review.

9.

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T.

Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.

PMID:
26941398
10.

[Evidence and recommendations for oncologic clinical exercise - a personalized treatment concept for cancer patients].

Baumann FT, Hallek M, Meyer J, Galvão DA, Bloch W, Elter T.

Dtsch Med Wochenschr. 2015 Sep;140(19):1457-61. doi: 10.1055/s-0041-104465. Epub 2015 Sep 24. German.

PMID:
26402184
11.

[Chemotherapy-induced Peripheral Neuropathy].

Bobylev I, Elter T, Schneider C, Wunderlich G, Zimmer P, Streckmann F, Fink GR, Lehmann HC.

Fortschr Neurol Psychiatr. 2015 Aug;83(8):427-36. doi: 10.1055/s-0035-1553475. Epub 2015 Sep 1. Review. German.

PMID:
26327474
12.

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B.

Haematologica. 2015 Nov;100(11):1451-9. doi: 10.3324/haematol.2015.124693. Epub 2015 Aug 27.

13.

Aerobic physical exercise for adult patients with haematological malignancies.

Bergenthal N, Will A, Streckmann F, Wolkewitz KD, Monsef I, Engert A, Elter T, Skoetz N.

Cochrane Database Syst Rev. 2014 Nov 11;(11):CD009075. doi: 10.1002/14651858.CD009075.pub2. Review. Update in: Cochrane Database Syst Rev. 2019 Jan 31;1:CD009075.

PMID:
25386666
14.

Impact of exercise on pro inflammatory cytokine levels and epigenetic modulations of tumor-competitive lymphocytes in Non-Hodgkin-Lymphoma patients-randomized controlled trial.

Zimmer P, Baumann FT, Bloch W, Schenk A, Koliamitra C, Jensen P, Mierau A, Hülsdünker T, Reinart N, Hallek M, Elter T.

Eur J Haematol. 2014 Dec;93(6):527-32. doi: 10.1111/ejh.12395. Epub 2014 Jun 28.

PMID:
24913351
15.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M.

Blood. 2014 Jul 3;124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5.

16.

Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.

Zimmer P, Mierau A, Bloch W, Strüder HK, Hülsdünker T, Schenk A, Fiebig L, Baumann FT, Hahn M, Reinart N, Hallek M, Elter T.

Leuk Lymphoma. 2015 Feb;56(2):347-52. doi: 10.3109/10428194.2014.915546. Epub 2014 Jun 5.

PMID:
24738942
17.

Characterization of novel mutants with an altered gibberellin spectrum in comparison to different wild-type strains of Fusarium fujikuroi.

Albermann S, Elter T, Teubner A, Krischke W, Hirth T, Tudzynski B.

Appl Microbiol Biotechnol. 2013 Sep;97(17):7779-90. doi: 10.1007/s00253-013-4917-7. Epub 2013 May 1.

PMID:
23636694
18.

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.

Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G.

Haematologica. 2013 May;98(5):765-70. doi: 10.3324/haematol.2012.076075. Epub 2013 Jan 8.

19.

Feasibility of an Isometric Maximal Voluntary Contraction Test in Hematological Cancer Patients during Thrombocytopenia.

Zimmer P, Baumann FT, Ebel J, Zopf EM, Bloch W, Elter T.

J Sports Med (Hindawi Publ Corp). 2013;2013:470489. doi: 10.1155/2013/470489. Epub 2013 Mar 21.

20.

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L.

Haematologica. 2013 Mar;98(3):364-70. doi: 10.3324/haematol.2012.077917. Epub 2012 Dec 14.

21.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

22.

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.

Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M.

Cancer Immunol Immunother. 2012 Dec;61(12):2367-73. doi: 10.1007/s00262-012-1362-x. Epub 2012 Oct 23.

PMID:
23090290
23.

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.

Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M.

Leukemia. 2012 Dec;26(12):2549-52. doi: 10.1038/leu.2012.129. Epub 2012 May 15. No abstract available.

PMID:
22584787
24.

Alemtuzumab for patients with chronic lymphocytic leukaemia.

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008078. doi: 10.1002/14651858.CD008078.pub2. Review.

25.

Influence of endurance exercise on the risk of pneumonia and Fever in leukemia and lymphoma patients undergoing high dose chemotherapy. A pilot study.

Baumann FT, Zimmer P, Finkenberg K, Hallek M, Bloch W, Elter T.

J Sports Sci Med. 2012 Dec 1;11(4):638-42. eCollection 2012.

26.

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A.

Lancet Oncol. 2011 Dec;12(13):1204-13. doi: 10.1016/S1470-2045(11)70242-X. Epub 2011 Oct 10.

PMID:
21992852
27.

Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia.

Kofler DM, Gawlik BB, Elter T, Gianella-Borradori A, Wendtner CM, Hallek M.

Leukemia. 2012 Apr;26(4):841-4. doi: 10.1038/leu.2011.286. Epub 2011 Oct 7. No abstract available.

PMID:
21979878
28.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.

J Clin Oncol. 2011 Sep 10;29(26):3559-66. doi: 10.1200/JCO.2010.33.8061. Epub 2011 Aug 15.

PMID:
21844497
29.

Alemtuzumab: what is the secret to safe therapy?

Elter T, Hallek M, Montillo M.

Clin Adv Hematol Oncol. 2011 May;9(5):364-73. Review.

PMID:
21685865
30.

Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation: benefits of a moderate exercise intervention.

Baumann FT, Zopf EM, Nykamp E, Kraut L, Schüle K, Elter T, Fauser AA, Bloch W.

Eur J Haematol. 2011 Aug;87(2):148-56. doi: 10.1111/j.1600-0609.2011.01640.x.

PMID:
21545527
31.

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.

Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG).

Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7.

PMID:
21139079
32.

Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?

Elter T, Stipanov M, Heuser E, von Bergwelt-Baildon M, Bloch W, Hallek M, Baumann F.

Int J Hematol. 2009 Sep;90(2):199-204. doi: 10.1007/s12185-009-0376-4. Epub 2009 Jul 24.

PMID:
19629631
33.

Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons.

Elter T, Eichhorst BF, Wendtner CM.

Curr Hematol Malig Rep. 2009 Jan;4(1):43-6. doi: 10.1007/s11899-009-0006-5.

PMID:
20425437
34.

Pharmacokinetics of alemtuzumab and the relevance in clinical practice.

Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C.

Leuk Lymphoma. 2008 Dec;49(12):2256-62. doi: 10.1080/10428190802475303. Review.

PMID:
19052972
35.

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A.

Haematologica. 2009 Jan;94(1):150-2. doi: 10.3324/haematol.13379. Epub 2008 Nov 10. No abstract available.

36.

Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.

Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M.

Ann Hematol. 2009 Feb;88(2):121-32. doi: 10.1007/s00277-008-0566-9. Epub 2008 Aug 6. Review.

PMID:
18682948
37.

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M.

Blood. 2008 Jan 1;111(1):109-11. Epub 2007 Oct 15.

PMID:
17938252
38.

Report on the 1st international workshop of the german competence network malignant lymphomas.

Re D, Elter T, Hallek M.

Onkologie. 2007 May;30(5):265-73. Epub 2007 Apr 25.

PMID:
17460423
39.

Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schröder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fätkenheuer G, Cornely OA.

Int J Antimicrob Agents. 2006 Sep;28(3):262-5.

PMID:
16908120
40.

Fludarabine in chronic lymphocytic leukaemia.

Elter T, Hallek M, Engert A.

Expert Opin Pharmacother. 2006 Aug;7(12):1641-51. Review.

PMID:
16872267
41.

Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.

Jensen M, Elter T, Engert A, Reiser M.

Onkologie. 2006 Mar;29(3):90-2. Epub 2006 Mar 3.

PMID:
16514269
43.

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.

J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.

PMID:
16145065
44.

Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.

Rothe A, Schulz H, Elter T, Engert A, Reiser M.

Haematologica. 2004 Jul;89(7):875-6.

45.

Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.

Maack C, Elter T, Böhm M.

Congest Heart Fail. 2003 Sep-Oct;9(5):263-70. Review.

46.

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.

Boye J, Elter T, Engert A.

Ann Oncol. 2003 Apr;14(4):520-35. Review. Erratum in: Ann Oncol. 2003 Jun;14(6):967.

47.

Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.

Krause AS, Weihrauch MR, Bode U, Fleischhack G, Elter T, Heuer T, Engert A, Diehl V, Josting A.

Leuk Lymphoma. 2002 Nov;43(11):2139-43.

PMID:
12533039
48.

Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.

Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stäblein A, Wuttke H, Böhm M.

J Am Coll Cardiol. 2001 Oct;38(4):939-46.

Supplemental Content

Support Center